Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Naoaki Sakata has a total of 534 co-authors. Here are the top co-authors by number of shared publications:

  • Michiaki Unno

    Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan

    49 shared publications
  • Shinichi Egawa

    Tohoku University

    45 shared publications
  • Fuyuhiko Motoi

    Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan

    36 shared publications
  • Takeshi Naitoh

    Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Japan

    34 shared publications
  • Yu Katayose

    Division of Gastroenterological Surgery, Department of Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan; Division of Integrated Surgery and Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan

    33 shared publications
  • Gumpei Yoshimatsu

    Department of Regenerative Medicine and Transplantation Faculty of Medicine Fukuoka University Jonan‐ku Fukuoka Japan

    31 shared publications

Latest Publications

  • Open Access

    WT1 peptide vaccines of post-allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase II study

    byĀ Yoshiko Hashii, Yoshihiro Oka, Naoki Sakata, Masashi Hirayama, Yusuke Oji, Naoki Hosen, Satoshi Hattori, Hiroko Nakajima, Jun Nakata, Fumihiro Fujiki, et al.

    This phase II clinical study evaluated the efficacy and safety of post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) maintenance cancer immunotherapy using two WT1 peptide vaccines-MCI-for pediatric refractory acute leukemias. Each of 17 patients (median age, 8.3 years; age range, 2-18 years) was intradermally injected with either of the vaccines. The 3-year overall survival (OS) rate-the primary endpoint-was 70.6% [95% confidence interval (CI), 43.1-86.6%]; this rate was higher than 30%, a historical control benchmark, and was attributable to the fact that 12 clinical responders-who sustained complete remission at year 1 after the initiation of vaccination-had a high 3-year OS rate of 91.7% (95% CI, 53.9-98.7%). WT1-specific cytotoxic T cell (CTL) frequency in peripheral blood (PB) from all of 12 clinical responders increased significantly after vaccination, reaching the maximum by week 12 of vaccination (before, 0.25±0.08%; after, 1.07±0.24%; P <.001), while WT1-specific CTL frequency in PB from clinical nonresponders remained unchanged after vaccination (before, 0.12±0.2%; after, 0.20±0.25%; P=.424). The estimated 3-year OS rate was significantly higher for 11 immune responders (who showed a ³1.455-fold increase from the baseline value: 90.9%) than for 5 immune nonresponders (40.0%; P=.027). Elevated WT1-specific CTL frequency in PB before vaccination predicted the subsequent favorable prognosis of all patients. No patients discontinued treatment due to MCI. Adverse events including graft-versus-host disease were manageable. MCI was suggested to be very effective and safe for pediatric patients with refractory acute leukemias, indicating its potential to improve their survival through relapse prevention. UMIN000005319

  • Open Access

    The Japanese Macaque as a Diabetes Recipient Animal Model for Porcine Islet Xenotransplantation

    byĀ Naoaki Sakata, Gumpei Yoshimatsu, Ryo Kawakami, Seiichi Tanaka, Shohta Kodama

    Porcine islet xenotransplantation is effective for severe diabetes; however, preclinical studies are essential. In this study, we evaluated the suitability of the Japanese macaque as a recipient model for islet xenotransplantation, including identifying the preferred method to induce diabetes. The safety and stability of the following four models to induce diabetes were assessed: Model 1: pancreatectomy, Model 2: pancreatectomy with low‐dose streptozotocin (STZ), Model 3: single‐injection of STZ, and Model 4: consecutive administrations of low‐dose STZ. Diabetes was induced in all four models. The blood glucose level after induction of diabetes was 225.32 ± 46.49 mg/dL in Model 1, 209.64 ± 64.36 mg/dL in Model 2, 175.51 ± 45.18 mg/dL in Model 3, and 139.22 ± 6.31 mg/dL in Model 4. Regarding safety, Models 1 and 2 involved invasive surgery with postoperative concerns. Model 3 induced diabetes in the Japanese macaques; however, the preferable dose of STZ was individual dependent. Among the models, Model 4 was preferable regarding safety and stability. Finally, we performed porcine islet xenotransplantation in a diabetic monkey in Model 4 and evaluated the therapeutic effects of this treatment. In conclusion, the Japanese macaque might be a possible recipient model for porcine islet xenotransplantation.


  • Open Access

    Polyclonal evolution of lymphoproliferative disorders in XLP1

    byĀ Dan Tomomasa, Akira Nishimura, Kenichi Yoshida, Yui Namikawa, Doo Ri Kim, Naoki Sakata, Kenichi Sakamoto, Takashi Taga, Yuta Sakai, Yasuhiro Ikawa, et al.

    X-linked lymphoproliferative syndrome type 1 (XLP1) is an inborn error of immunity caused by pathogenic variants in SH2D1A and is frequently complicated by Epstein-Barr virus (EBV)–associated lymphoproliferative disorders (LPDs). However, cases of LPD without EBV infection have been reported and remain poorly understood. We investigated tumorigenesis mechanisms through transcriptomic profiling and somatic variant analysis in tumor samples from six patients with XLP1. Pathogenic variants were identified in two: one developed two distinct LPDs harboring CARD11/GNA13 and MECOM variants, while the other carried IRF4, P2RY8, KRAS, and CCND3 variants. Transcriptome analysis of three tumors, compared with diffuse large B cell lymphoma from patients without an underlying immune defect, revealed a distinct expression profile. Gene Ontology analysis showed upregulation of adaptive immune response genes, including various IgH and TCR genes, suggesting polyclonal lymphocyte proliferation. Overall, LPD associated with XLP1 may originate from polyclonal lymphocyte expansion, either in the presence or absence of EBV infection, and subsequently progress to malignancy through somatic variants.

  • Open Access

    Editorial: Cellular replacement therapy for diabetes

    byĀ Naoaki Sakata, Gumpei Yoshimatsu, Shohta Kodama

    Diabetes mellitus (DM) is a metabolic disorder with chronic hyperglycemia due to insulin deficiency and/or impaired insulin action. DM is a common disease, but it often threatens a patient’s quality of life. Cellular replacement therapy using insulin-producing cells is a promising therapy for severe DM because of the proper provision of internal insulin according to a change in blood glucose concentrations. This Special Collection, ā€œCellular Replacement Therapy for Diabetes,ā€ was planned to appeal the current status and present novel translational trials of this therapy. Ten specialists presented their research, which attempted to overcome three limitations of the current cellular replacement therapy, including the regulation of immunity, limited donor supplies, and establishment of a preferable transplant site for cellular replacement therapy. Regarding regulation of immunity, potential of mesenchymal stem cells and immunomodulatory splenocytes is clarified. Regarding alternative donors, the current status of porcine islet xenotransplantation and therapy using multipotent stem cell–derived cells is introduced. And regarding transplant site, possibility of liver surface and subcutaneous tissue is elucidated.

  • Open Access

    Safe Administration of Immunosuppression in Japanese Monkeys: Relevance to Preclinical Xenotransplantation Studies

    byĀ Naoaki Sakata, Gumpei Yoshimatsu, Ryo Kawakami, Shohta Kodama

    The Japanese monkey has been used in several animal studies; however, its potential as a recipient model for xenotransplantation is unclear. The potential of the Japanese monkey as a recipient for xenotransplantation was assessed using two experimental models. The first model evaluated the optimal dose of tacrolimus without severe adverse events. The plasma tacrolimus levels, blood counts, and hepatic and renal function tests were evaluated. The second model assessed the immunosuppressive effects of thymoglobulin and tacrolimus. Immunosuppression was evaluated using blood counts and flow cytometry to measure lymphocytes in peripheral blood mononuclear cells (PBMCs). In the first model, the target trough level (10–15 ng/ml) was achieved and maintained with tacrolimus administration at 1.6 mg/kg/day in all monkeys. There were no adverse events related to the blood count or to liver, kidney, or nutrient parameters at this dose, except for hemoglobin. In the second model, a decrease in white blood cells was observed. Flow cytometry revealed a temporary decrease in T- and B-cell numbers among PBMCs on day 4. We consider that the Japanese monkey is acceptable to be used as a recipient model for preclinical xenotransplantation. The safe administration of tacrolimus and thymoglobulin is clarified for this model.


  • Open Access

    Effectiveness Evaluation of Microneedling Therapy for Diabetic Ulcer: An Animal Model Study

    byĀ Eri Morinaga, Naoaki Sakata, Ryo Msc Kawakami, Reiko Naito, Gumpei Yoshimatsu, Satoshi Takagi, Shohta Kodama

    Background: Diabetic ulcer is an intractable complication seen in nearly 6% of diabetes patients. Some patients with diabetic ulcers cannot avoid femoral amputation by the current standard treatments. Therefore, a novel and effective radical cure therapy is needed. Microneedling is a widely applied wound-healing treatment in cosmetic medicine. In this study, we evaluated the therapeutic effects of microneedling on diabetic ulcers using an animal model. Methods: Nine- to 10-week-old male C57BL/6J mice with drug-induced diabetes received full-thickness skin removal on the back. The mice with and without microneedling were classified into microneedling and nontreatment groups, respectively. The therapeutic effects of microneedling were assessed by wound closure rate by 14 days after the treatment and histological assessments in the wound. Results: The wound closure rate was significantly higher in the microneedling group than in the nontreatment groups from 7 days after microneedling (wound closure rate: 63.0 ± 10.2% versus 36.6 ± 12.1%). Histological assessments revealed that microneedling induced infiltration of neutrophils and M1 macrophages into the microhemorrhage region within 12 hours. The macrophages shifted to M2 macrophages 4 days after microneedling. Hyperexpression of transforming growth factor beta 1 was confirmed 7 days after microneedling. After that, the promotion of collagen proliferation and neovascularization were seen 10 and 14 days after microneedling, respectively. Conclusions: Our data clarified that microneedling was effective for wound healing in an animal model of diabetic ulcer. This study has limitations correlated with small animal models and acute surgical wounds. Future clinical trials are recommended.

  • Open Access

    Influence of relatively short-term culture on adult porcine islets for xenotransplantation

    byĀ Naoaki Sakata, Gumpei Yoshimatsu, Ryo Kawakami, Shohta Kodama

    Porcine islet xenotransplantation is a promising therapy for severe diabetes mellitus. Maintenance of the quality and quantity of porcine islets is important for the success of this treatment. Here, we aimed to elucidate the influence of relatively short-term (14 days) culture on adult porcine islets isolated from three micro-minipigs (P111, P112 and P121). Morphological characteristics of islets changed little after 14 days of culture. The viability of cultured islets was also maintained at a high level (> 80%). Furthermore, cultured islets exhibited similar glucose-stimulated insulin secretion and insulin content at Day 14 were preserved comparing with Day 1, while the expressions of Ins, Gcg and Sst were attenuated at Day 14. Xenotransplantation using diabetic nude mice showed no normalization of blood glucose but increased levels of plasma porcine C-peptide after the transplantation of 14 day cultured porcine islets. Histological assessment revealed that relatively short-term cultured porcine islets were successfully engrafted 56 days following transplantation. These data show that relatively short-term culture did not impair the quality of adult porcine islets in regard to function, morphology, and viability. Prevention of impairment of gene correlated with endocrine hormone is warranted for further improvement.


  • Open Access

    The porcine islet-derived organoid showed the characteristics as pancreatic duct

    byĀ Naoaki Sakata, Gumpei Yoshimatsu, Ryo Kawakami, Kazuaki Nakano, Teppei Yamada, Akihiro Yamamura, Hiroshi Nagashima, Shohta Kodama

    Organoid is a tissue-engineered organ-like structure that resemble as an organ. Porcine islet-derived organoid might be used as an alternative donor of porcine islet xenotransplantation, a promising therapy for severe diabetes. In this study, we elucidated the characteristics of porcine islet organoids derived from porcine islets as a cell source for transplantation. Isolated porcine islets were 3D-cultured using growth factor-reduced matrigel in organoid culture medium consist of advanced DMEM/F12 with Wnt-3A, R-spondin, EGF, Noggin, IGF-1, bFGF, nicotinamide, B27, and some small molecules. Morphological and functional characteristics of islet organoids were evaluated in comparison with 2D-cultured islets in advanced DMEM/F12 medium. Relatively short-term (approximately 14 days)—cultured porcine islet organoids were enlarged and proliferated, but had an attenuated insulin-releasing function. Long-term (over a month)—cultured islet organoids could be passaged and cryopreserved. However, they showed pancreatic duct characteristics, including cystic induction, strong expression of Sox9, loss of PDX1 expression, and no insulin-releasing function. These findings were seen in long-term-cultured porcine islets. In conclusion, our porcine islet organoids showed the characteristics of pancreatic ducts. Further study is necessary for producing porcine islet-derived organoids having characteristics as islets.


  • Open Access

    Efficacy of Neonatal Porcine Bone Marrow–Derived Mesenchymal Stem Cell Xenotransplantation for the Therapy of Hind Limb Lymphedema in Mice

    byĀ Yuichi Morita, Naoaki Sakata, Masuhiro Nishimura, Ryo Kawakami, Masayuki Shimizu, Gumpei Yoshimatsu, Osamu Sawamoto, Shinichi Matsumoto, Hideichi Wada, Shohta Kodama

    Lymphedema is an intractable disease with few effective therapeutic options. Autologous mesenchymal stem cell (MSC) transplantation is a promising therapy for this disease. However, its use is limited by the cost and time for preparation. Recently, xenotransplantation of porcine MSCs has emerged as an alternative to autologous MSC transplantation. In this study, we aimed to clarify the usefulness of neonatal porcine bone marrow–derived MSC (NpBM-MSC) xenotransplantation for the treatment of lymphedema. One million NpBM-MSCs were xenotransplanted into the hind limbs of mice with severe lymphedema (MSC transplantation group). The therapeutic effects were assessed by measuring the femoral circumference, the volume of the hind limb, the number and diameter of lymphatic vessels in the hind limb, and lymphatic flow using a near-infrared fluorescence (NIRF) imaging system. We compared the effects using mice with lymphedema that did not undergo NpBM-MSC transplantation (negative control group). The condition of the transplanted NpBM-MSCs was also evaluated histologically. The femoral circumference and volume of the hind limb had been normalized by postoperative day (POD) 14 in the MSC transplantation group, but not in the negative control group ( P = 0.041). NIRF imaging revealed that lymphatic flow had recovered in the MSC transplantation group by POD 14, as shown by an increase in luminance in the hind limb. Histological assessment also showed that the xenotransplantation of NpBM-MSC increased the proliferation of lymphatic vessels, but they had been rejected by POD 14. The xenotransplantation of NpBM-MSCs is an effective treatment for lymphedema, and this is mediated through the promotion of lymphangiogenesis.


  • Open Access

    Rescue of murine hind limb ischemia via angiogenesis and lymphangiogenesis promoted by cellular communication network factor 2

    byĀ Masayuki Shimizu, Gumpei Yoshimatsu, Yuichi Morita, Tomoko Tanaka, Naoaki Sakata, Hideaki Tagashira, Hideichi Wada, Shohta Kodama

    Critical limb ischemia (CLI) is caused by severe arterial blockage with reduction of blood flow. The aim of this study was to determine whether therapeutic angiogenesis using cellular communication network factor 2 (CCN2) would be useful for treating CLI in an animal model. Recombinant CCN2 was administered intramuscularly to male C57BL/6J mice with hind limb ischemia. The therapeutic effect was evaluated by monitoring blood flow in the ischemic hind limb. In an in vivo assay, CCN2 restored blood flow in the ischemic hind limb by promoting both angiogenesis and lymphangiogenesis. VEGF-A and VEGF-C expression levels increased in the ischemic limb after treatment with CCN2. In an in vitro assay, CCN2 promoted proliferation of vascular and lymphatic endothelial cells, and it upregulated expression of Tgfb1 followed by expression of Vegfc and Vegfr3 in lymphatic endothelial cells under hypoxia. Suppression of Tgfb1 did not affect the activity of CCN2, activation of the TGF-β/SMAD signaling pathway, or expression of Vegfr3 in lymphatic endothelial cells. In summary, treatment using recombinant CCN2 could be a promising therapeutic strategy for CLI.